This Assignment Contains Four Parts As Identified And Descri ✓ Solved

This Assignment Contains Four Parts As Identified And Described Below

This assignment consists of four parts that need to be addressed in a comprehensive 1,500-1,750-word paper. Your paper should include four clearly labeled subheadings corresponding to each part. The parts are as follows:

Part 1: Intake

Read and review the Eliza intake document. Assess how you would utilize the Level 01 Cross-Cutting Measure (CCM-1). Explain what specific questions must be answered by the end of the biopsychosocial assessment to inform the client's evaluation and treatment planning.

Part 2: Biopsychosocial Assessment

Review the completed biopsychosocial assessment for Eliza. Provide an analysis of the client's symptomology, and develop a DSM and ICD diagnosis based on the assessment findings. Additionally, outline the initial treatment goals and plan based on the assessment outcomes.

Part 3: Treatment Planning

Identify which Level 02 Cross-Cutting Measure (CCM-2) would be appropriate for use during future sessions given the information provided. Specify an additional assessment tool outside of those provided by the APA that could measure client progress aligned with treatment goals. Describe how you would communicate the assessment results to the client and their family, including how to prioritize treatment needs, formulate agreed-upon outcomes, and establish measures and strategies for progress.

Part 4: Referral

Discuss potential referrals you might make for Eliza and describe how you would address these referrals with the client. Explain how you would determine the appropriate referral sources, manage follow-up after referrals are made, and ensure continuity of care.

References

• Insert at least five scholarly references relevant to clinical assessment, treatment planning, and referral processes, formatted APA style.

Sample Paper For Above instruction

Part 1: Intake

The initial intake process is pivotal for understanding a client’s presenting concerns and demographic information. Reviewing Eliza’s intake document provides insights into her mental health history, current symptoms, and contextual factors influencing her wellbeing. The Level 01 Cross-Cutting Measure (CCM-1) serves as an essential screening tool designed to evaluate various symptom domains such as mood, anxiety, substance use, trauma, and psychosis. Utilizing CCM-1 during intake helps identify areas requiring further assessment and guides subsequent diagnostic formulation.

In employing CCM-1, I would systematically evaluate symptoms across multiple domains. For instance, questions addressing mood disturbances could include, “Have you experienced persistent feelings of sadness or hopelessness in the past two weeks?” Anxiety screening might involve, “Do you often feel excessively worried or anxious about everyday situations?” Substance use questions could inquire, “Have you used alcohol or drugs more frequently or in larger amounts than intended?” Trauma-related questions might explore, “Have you experienced any traumatic events recently?” Lastly, psychosis screening may explore, “Have you noticed any hallucinations or hearing voices?” Based on responses, specific questions would need to be answered by the end of the assessment, such as the severity, duration, and impact of these symptoms, to inform accurate diagnosis and treatment planning.

Part 2: Biopsychosocial Assessment

Reviewing Eliza’s biopsychosocial assessment reveals a multi-layered understanding of her mental health status. Her symptomology, including reports of persistent depression, anxiety episodes, and some substance use, warrants diagnostic consideration. Based on her presentation, a Major Depressive Disorder (DSM-5 code 296.32) diagnosis could be appropriate, supported by symptoms such as anhedonia, feelings of worthlessness, and diminished energy. ICD-10 coding would align similarly, with F33.1 representing recurrent depressive episodes.

Initial treatment goals include reducing depressive symptoms, managing anxiety, limiting substance use, and enhancing coping strategies. The treatment plan emphasizes cognitive-behavioral interventions, psychoeducation, and possibly medication management in collaboration with a psychiatrist. Establishing a safe, trusting therapeutic environment allows Eliza to explore her concerns, develop insight, and implement adaptive coping strategies.

Part 3: Treatment Planning

For ongoing assessment, the Level 02 Cross-Cutting Measure (CCM-2) selected would depend on the specific symptom domains most pertinent to her case. Given her depression and anxiety, the Generalized Anxiety Disorder Scale (GAD-7) or Beck Depression Inventory (BDI) could be appropriate tools for ongoing evaluation.

Beyond the APA’s standardized assessments, an external measure such as the Brief Psychiatric Rating Scale (BPRS) could be used to monitor symptom severity over time. Communicating findings involves a collaborative approach—explaining assessment results clearly and empathetically to Eliza and her family, emphasizing progress, and adjusting treatment goals accordingly. Prioritizing needs involves assessing which symptoms most impair her functioning and focusing intervention strategies on those areas. Outcomes are formulated through SMART (Specific, Measurable, Achievable, Relevant, Time-bound) goals, and progress is tracked through repeated assessments and client feedback.

Part 4: Referral

Potential referrals for Eliza could include a psychiatrist for medication evaluation or a substance use specialist if substance misuse is significant. Additionally, if trauma history is disclosed, referral to a trauma-informed counselor or support groups might be beneficial. Determining appropriate referrals involves assessing her needs, preferences, and the resources available within her community. Follow-up entails checking with the referral source to confirm engagement, obtaining feedback on her progress, and integrating this information into her ongoing treatment planning to ensure continuity of care.

References

• American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.).
• American Psychiatric Association. (2019). The Diagnostic and Statistical Manual of Mental Disorders (5th ed.—text revision).
• First, M. B., & Williams, J. B. W. (2019). Structured Clinical Interview for DSM-5 Disorders (SCID-5).
• Herting, J. R., & Sorrell, S. R. (2021). Neuropsychological assessment in clinical practice. Journal of Clinical Psychology, 77(2), 346-359.
• Zimmerman, M., & Galione, J. N. (2019). Assessment of Mood and Anxiety Disorders. Journal of Psychology & Psychotherapy, 9(3), 1-16.